Table 4 Anti-malarials received
| Â | Public | Medicine retailer | Total | Â |
|---|---|---|---|---|
% (95% CI) | % (95% CI) | % (95% CI) | P value | |
Anti-malarials received (all ages) | N = 466 | N = 1176 | N = 1642 | Â |
% of patients (of all ages) that received: | Â | Â | Â | Â |
   an anti-malarial | 54.2 (44.1-63.9) | 81.5 (76.2-85.8) | 79.3 (74.5-83.4) | <0.001 |
   any ACT†| 17.3 (9.0-30.5) | 22.8 (17.2-29.7) | 22.4 (17.0-28.8) | 0.378 |
   Artemisinin monotherapy* | 2.0 (0.8-5.2) | 14.4 (11.4-18.0) | 13.4 (10.6-16.7) | <0.001 |
   Amodiaquine | 0.1 (0.00-1.0) | 2.0 (0.9-4.6) | 1.9 (0.8-4.2) | 0.002 |
   Chloroquine | 2.4 (0.5-10.6) | 3.3 (2.0-5.4) | 3.2 (2.0-5.2) | 0.673 |
   Quinine | 0 | 0.9 (0.3-2.2) | 0.8 (0.3-2.0) | 0.501 |
   SP | 33.6 (20.9-49.1) | 38.2 (31.8-45.1) | 37.9 (31.8-44.3) | 0.546 |
Anti-malarials received (children < 5 yrs only) | N = 193 | N = 107 | N = 300 | Â |
% of children <5 years that received: | Â | Â | Â | Â |
   an anti-malarial | 33.2 (20.0-49.7) | 80.2 (63.6-90.4) | 67.1 (53.7-78.1) | 0.001 |
   any ACT‡ | 21.3 (9.9-39.9) | 31.6 (18.2-49.0) | 28.7 (18.0-42.6) | 0.329 |
   Artemisinin monotherapy* | 2.0 (0.2-14.5) | 10.2 (3.4-26.8) | 7.9 (2.9-20.2) | 0.110 |
   Amodiaquine | 0.2 (0.0-3.0) | 9.3 (2.3-30.6) | 6.7 (1.6-23.8) | 0.001 |
   Chloroquine | 1.5 (0.7-3.2) | 12.6 (4.2-32.1) | 9.5 (3.5-23.5) | 0.001 |
   Quinine | 0 | 4.5 (0.6-26.8) | 3.23 (0.5-20.2) | 0.497 |
   SP | 9.2 (3.7-21.0) | 19.9 (8.5-40.0) | 16.9 (8.1-32.0) | 0.176 |
Type of ACT received | N = 105 | N = 210 | N = 315 | Â |
% AL | 96.5 (92.5-98.4) | 40.2 (26.9-55.1) | 43.6 (31.0-57.2) | <0.001 |
% ASAQ | 3.0 (1.4-6.2) | 28.5 (16.1-45.2) | 26.9 (15.3-42.8) | <0.001 |
% DHAPQ | 0 | 24.3 (15.1-36.5) | 22.8 (14.3-34.3) | 0.074 |
% ASMQ | 0.5 (0.1-1.9) | 4.1 (0.9-16.6) | 3.9 (0.9-15.5) | 0.019 |
% ASSP | 0 | 2.9 (0.7-11.5) | 2.8 (0.7-10.8) | 0.648 |